Trial Profile
Efficacy of Palivizumab in Preventing RSV-Associated Hospitalization in High-Risk Infants and Children
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2015
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 22 Dec 2015 New trial record